Healthcare Industry News: XTENT
News Release - February 1, 2007
XTENT, Inc. Announces Pricing of Initial Public OfferingMENLO PARK, Calif., Feb. 1 (HSMN NewsFeed) -- XTENT, Inc. (Nasdaq: XTNT ) today announced the initial public offering of 4,700,000 shares of common stock at a price of $16.00 per share. XTENT has granted the underwriters an option to purchase up to an additional 705,000 shares at the initial public offering price to cover over-allotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "XTNT".
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of XTENT, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the final prospectus may be obtained from the offices of Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, Minnesota 55402; Cowen and Company, LLC at ADP, 1155 Long Island Avenue, Edgewood, NY 11717; Lazard Capital Markets LLC at 30 Rockefeller Plaza, New York, NY 10020; and RBC Capital Markets Corporation at One Liberty Plaza, 165 Broadway, New York, NY 10006.
About XTENT, Inc.
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT® Custom NX(TM) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.